← Search & browse all drugs
VARIOUS › DIAGNOSTIC RADIOPHARMACEUTICALS › SKELETON › Technetium (99mTc) compounds
technetium (99mTc) oxidronic acid
V09BA01
Forms & Strengths
- Sterile lyophilized kit (1-2 mL) for reconstitution with Na99mTcO4
- Ready‑to‑use solution containing 10‑30 mCi (370‑1110 MBq) per vial
- Single‑dose vials, preservative‑free
Adult Dosing
- 20‑30 mCi (740‑1110 MBq) IV bolus for routine bone scan
- 10‑20 mCi for whole‑body survey or low‑dose protocol
- Imaging 2‑4 h after injection; delayed images up to 24 h if needed
- Maximum cumulative activity per study ≈30 mCi
Pediatric Dosing
- 0.5‑2 mCi/kg IV (18‑74 MBq/kg), not to exceed 20 mCi total
- Typical dose 5‑10 mCi for infants and small children
- Imaging 2‑4 h post‑injection; adjust timing for cooperation
- Weight‑based dosing recommended for safety
Indications
- Skeletal metastasis detection in cancer patients
- Evaluation of unexplained bone pain, fractures, or osteomyelitis
- Assessment of prosthetic joint loosening or hardware complications
- Screening for metabolic bone diseases (Paget, hyperparathyroidism)
- Whole‑body bone scintigraphy for trauma or infection work‑up
Mechanism of Action
- 99mTc binds to oxidronate (diphosphonate) forming a complex with high affinity for hydroxyapatite
- Localizes in areas of active osteoblastic turnover and increased blood flow
- Gamma emission (140 keV) enables planar or SPECT imaging of bone metabolism
Contraindications
- Known hypersensitivity to oxidronate or kit excipients
- Severe renal impairment precluding safe excretion (relative)
- Pregnancy – use only if benefit outweighs fetal radiation risk
- Breast‑feeding – discontinue nursing for 24 h after administration
Adverse Reactions
- Mild injection‑site pain or erythema
- Transient nausea, flushing, or dizziness
- Rare allergic reactions: urticaria, bronchospasm, anaphylaxis
- Hypotension (rare, usually with rapid injection)
- Radiation exposure – stochastic risk, negligible at diagnostic doses
Drug Interactions
- Calcium supplements or high‑dose vitamin D may reduce skeletal uptake
- Concurrent bisphosphonate therapy can compete for binding sites
- Tetracyclines and other chelating agents may alter biodistribution
- No clinically significant interactions with most cardiovascular or CNS drugs
Curated Content: Needs Vetting Before Put to Clinical Use